Filing Analysis
Prothena Corporation announced its financial results for the second quarter ended June 30, 2026. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: August 6, 2026
- Reporting period: Second Quarter ended June 30, 2026
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Prothena Corporation announced the resignation of Board member Paula Cobb, effective December 31, 2025. The company explicitly stated that her departure is not due to any disagreement regarding operations, policies, or practices.
📋 Key Facts
- Paula Cobb will resign from the Board of Directors effective December 31, 2025.
- Ms. Cobb will continue serving on the Board, Compensation Committee, and Audit Committee through her departure date.
- The resignation is not related to any disagreement with the Company's operations, policies, or practices.
Prothena Corporation held an extraordinary general meeting on November 19, 2025, where shareholders approved a proposal to reduce the company's capital to create distributable reserves. This is a common corporate action used to facilitate dividend payments or return capital to shareholders.
📋 Key Facts
- Extraordinary general meeting held on November 19, 2025.
- Proposal No. 1: Approval of a Reduction of the Company’s Capital to Create Distributable Reserves was approved by shareholders.
- Voting results for Proposal No. 1: 37,779,052 For; 46,738 Against; 45,906 Abstain.
Prothena Corporation announced its financial results for the third quarter ended September 30, 2025. The filing serves as a formal notification of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing includes a press release regarding financial results as Exhibit 99.1.
Prothena Corporation issued an 8-K to announce clinical trial results from its Phase 1 ASCENT program regarding the investigational drug PRX012. The filing serves as a vehicle to incorporate a press release containing these updates into the company's official SEC record.
📋 Key Facts
- Date of report: August 27, 2025
- Subject matter: Update on investigational drug PRX012 and Phase 1 ASCENT clinical program results
- The filing incorporates a press release dated August 27, 2025, as Exhibit 99.1
Prothena Corporation announced that its partner, Novo Nordisk, has decided to advance the drug coramitug into Phase 3 clinical development for ATTR amyloidosis with cardiomyopathy. This represents a significant milestone in the company's partnership-driven development pipeline.
📋 Key Facts
- Partnered company Novo Nordisk is advancing coramitug into Phase 3 development.
- Target indication: ATTR amyloidosis with cardiomyopathy.
- Announcement date: August 6, 2025.
Prothena Corporation announced its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025
- Announcement date: August 4, 2025
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Prothena Corporation plc announced that its subsidiary, Prothena Biosciences Inc, has entered into new employment agreements with three key executives: the CFO/CSO, COO, and CSO. These agreements formalize base salaries, bonus targets, and severance packages for these officers.
🚩 Red Flags
- Formalization of significant severance packages (double-trigger/change in control provisions) can be viewed as a defensive measure or preparation for a potential M&A event, though standard for many micro-cap biotech firms.
📋 Key Facts
- Tran B. Nguyen (CFO & Chief Strategy Officer) annual base salary: $603,792; target bonus: 50%.
- Brandon S. Smith (COO) annual base salary: $544,201; target bonus: 50%.
- Wagner M. Zago, Ph.D. (CSO) annual base salary: $518,000; target bonus: 40%.
- Severance terms include 100% of base and target bonus for termination without cause.
- Change in control severance increases to 150% of base and target bonus.
Prothena Corporation announced a massive 63% workforce reduction following the discontinuation of its birtamimab development program. The restructuring aims to reduce operating costs and will result in significant severance charges and the departure of two key executives.
🚩 Red Flags
- Massive workforce reduction (63%) indicates significant strategic pivot or distress in core pipeline.
- Discontinuation of a major development program (birtamimab).
- Departure of two C-suite officers (Chief Regulatory Officer and Chief People Officer) during restructuring.
- Significant one-time cash charges ($16M-$20M) impacting near-term liquidity.
📋 Key Facts
- Workforce reduction of approximately 63% of total employees.
- Discontinuation of the development of 'birtamimab' announced on May 23, 2025.
- Estimated $16 million to $20 million in total severance and related benefit charges.
- Termination of Chief Regulatory Officer Carol D. Karp and Chief People Officer David A. Ford, effective August 1, 2025.
- Workforce reduction expected to be substantially complete by the end of Q4 2025.
Prothena Corporation announced that its partner, Roche, has decided to advance the drug candidate prasinezumab into Phase III clinical development for early-stage Parkinson’s disease.
📋 Key Facts
- Partner company (Roche) is advancing prasinezumab into Phase III development.
- Target indication: Early-stage Parkinson's disease.
- Announcement date: June 15, 2025.
Prothena Corporation announced the discontinuation of the development of birtamimab following results from its Phase 3 AFFIRM-AL clinical trial for AL amyloidosis. The filing serves to communicate a significant setback in the company's clinical pipeline.
🚩 Red Flags
- Discontinuation of a Phase 3 clinical asset (birtamimab) represents a significant loss of R&D investment and potential future revenue stream.
- Failure in a late-stage trial (Phase 3) is a high-impact negative event for biotech companies.
📋 Key Facts
- Date of report: May 23, 2025
- Clinical Trial: Phase 3 AFFIRM-AL trial for birtamimab
- Indication: Patients with AL amyloidosis
- Outcome: Discontinuation of further development of birtamimab
Prothena Corporation held its Annual General Meeting on May 13, 2025. Shareholders approved an amendment to the 2018 Long Term Incentive Plan (LTIP) and re-elected several directors.
🚩 Red Flags
- Significant 'Against' votes on Proposal 3 (Executive Compensation) and Proposal 4 (LTIP Amendment), suggesting shareholder dissatisfaction with pay or dilution.
📋 Key Facts
- Annual Meeting held on May 13, 2025.
- Shareholders approved an amendment to the 2018 LTIP increasing authorized shares for issuance by 2,000,000 ordinary shares.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year 2025 via a non-binding vote.
- Paula K. Cobb, Lars G. Ekman, and Gene G. Kinney were re-elected to the Board of Directors.
- Shareholders approved executive compensation in a non-binding advisory vote.
Prothena Corporation plc filed an 8-K to announce its financial results for the first quarter ended March 31, 2025. The filing serves as a formal notice that a press release containing these results was issued on May 8, 2025.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025.
- Filing date: May 8, 2025.
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
Prothena Corporation announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. The filing serves as a placeholder to furnish the earnings press release via Exhibit 99.1.
📋 Key Facts
- Reported date: February 20, 2025
- Reporting period: Fourth quarter and fiscal year ended December 31, 2024
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Oleg Nodelman has resigned from the Board of Directors of Prothena Corporation, effective December 31, 2024. The resignation is reportedly to allow him to focus on other endeavors and was not due to any disagreement with the company.
📋 Key Facts
- Oleg Nodelman will resign from the Board of Directors effective December 31, 2024.
- The departure is intended to allow the director time to focus on existing and new endeavors.
- Nodelman will continue serving on the Compensation Committee and Nominating and Corporate Governance Committee through his effective date.
- The company explicitly states there was no disagreement regarding operations, policies, or practices.
Prothena Corporation announced its financial results for the third quarter ended September 30, 2024. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
Prothena Corporation announced the resignation of its Chief Medical Officer, Hideki Garren, M.D., Ph.D., effective September 27, 2024. Dr. Garren is leaving to pursue an opportunity at a large pharmaceutical company.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in the biotechnology sector can impact clinical development momentum and investor confidence.
📋 Key Facts
- Hideki Garren, M.D., Ph.D., resigned as Chief Medical Officer on September 23, 2024.
- The resignation becomes effective on September 27, 2024.
- Reason for departure: To pursue an opportunity at a large pharmaceutical company.
Prothena Corporation announced its financial results for the second quarter ended June 30, 2024. The filing serves as a formal notification of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024
- Filing date: August 8, 2024
- The filing is an announcement of financial results under Item 2.02.
Prothena Corporation has entered into a Global License Agreement with Bristol Myers Squibb (BMS) regarding the PRX019 research program. The agreement grants BMS exclusive global rights to develop and commercialize antibody products targeting specified targets, involving significant upfront and milestone payments.
🚩 Red Flags
- Milestone payments and royalties are subject to reductions if BMS develops improved versions of the product.
- BMS retains rights to terminate the agreement for certain safety reasons.
📋 Key Facts
- BMS exercised its IND Option for the PRX019 research program.
- Prothena receives an upfront payment of $80 million.
- Potential development/regulatory milestones totaling up to $242.5 million.
- Potential sales-based milestones totaling up to $375 million.
- Tiered royalties ranging from high single digits to high teens on net sales.
- Prothena is obligated to run the Phase 1 clinical trial for PRX019, though BMS has the option to take over this responsibility.
Prothena Corporation held its Annual General Meeting on May 14, 2024. Shareholders approved an amendment to the 2018 Long Term Incentive Plan (LTIP) and re-elected several directors.
📋 Key Facts
- Annual Meeting held on May 14, 2024.
- Shareholders approved an amendment to the 2018 LTIP, increasing authorized shares for issuance by 2,000,000 ordinary shares.
- Four directors (Richard T. Collier, Shane M. Cooke, William H. Dunn, Jr., and Daniel G. Welch) were re-elected to terms ending in 2027.
- Shareholders ratified the appointment of KPMG LLP as independent auditor for fiscal year 2024.
- Shareholders approved executive compensation via a non-binding advisory vote.
Prothena Corporation issued an 8-K to announce its financial results for the first quarter ended March 31, 2024. The filing serves as a formal notice that the quarterly earnings press release is being furnished to the SEC.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Announcement date: May 8, 2024.
- The filing includes a press release (Exhibit 99.1) regarding results of operations and financial condition.
Prothena Corporation announced the appointment of Daniel G. Welch to the Board of Directors, effective February 21, 2024. Mr. Welch will serve as Chair Designate and is expected to become Chair of the Board following shareholder election at the next annual meeting.
📋 Key Facts
- Daniel G. Welch appointed to the Board of Directors on February 21, 2024.
- Welch designated as 'Chair Designate' with intent to assume Chair role after shareholder election.
- Granted an option to acquire 132,000 ordinary shares under the 2018 Long Term Incentive Plan.
- Option exercise price set at the last reported sale price on Nasdaq as of February 21, 2024.
- Options vest in equal annual installments over five years subject to continuous service.
- Annual cash retainer of $90,000 for service as Chair Designate and subsequent Chair.
Prothena Corporation announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. This is a routine earnings release filing.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended December 31, 2023.
- Filing date: February 15, 2024.
- The report includes the announcement of financial results via a press release (Exhibit 99.1).
Prothena Corporation announced preliminary financial results for the period ending December 31, 2023. The company expects to report approximately $621 million in cash, cash equivalents, and restricted cash.
📋 Key Facts
- Expected cash, cash equivalents, and restricted cash: ~$621 million as of Dec 31, 2023.
- The announcement was made on January 8, 2024.
- Preliminary estimate based on currently available information; final figures subject to year-end audit/closing.